Ethics approval The study protocol was approved by the Research Data Governance of the CPRD (protocol 22_002276) and by the Research Ethics Board of the Jewish General Hospital, Montreal, Canada
"N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis." J Nutr
Inhibition of GCS It is well known [27, 41] that GSH is a competitive inhibitor against glutamate of GCS, the enzyme that catalyzes the synthesis of glutamyl-cysteine
Funding Department of Biotechnology-Basic Research in Modern Biology, DBT (BRB): BT/PR8226/BRB/10/1224/2013, Venketesh Sivaramakrishnan, Department of Science and Technology-The Science and Engineering Research BoardExtra Mural Research, DST-SERB-EMR: EMR/2017/005381, Venketesh Sivaramakrishnan,University Grants Commission-Special Assistance Program (UGC-SAP III), F.3-19 /2018/DRS-III(SAP-II), Venketesh Sivaramakrishnan, Bioinformatics Infrastructure Facility, Indian Institute of Technology Madras, DBT-BIF: BT/BI/25/063/2012, Venketesh Sivaramakrishnan, King Saud University, ORF-2025-143, Natarajan Arumugam
Therefore, clinicians are asked to consider these therapies for PDAC risk reduction, provided there are no contraindications